Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viatris Inc. (VTRS) P/S ratio

Alert me on P/S ratio

As of 16 October 2026, Viatris Inc. (VTRS) trades at a P/S ratio of 1.5×. Over the past ten years it has ranged from 0.6× (March 2020) to 4.2× (July 2015); the current reading is higher than 69% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 2.1× and below the Healthcare sector median of 3.4×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 1.0× 1.12%
FY2024 1.0× 13.74%
FY2023 0.9× 4.48%
FY2022 0.8× (7.24%)
FY2021 0.9× (3.04%)
FY2020 0.9× 4.64%
FY2019 0.9× (26.90%)
FY2018 1.2× (36.29%)
FY2017 1.9× 6.83%
FY2016 1.8× (33.11%)

Quarterly newest first

Period P/S ratio Change
Jun 2026 1.3× 16.94%
Mar 2026 1.1× 5.16%
Dec 2025 1.0× 24.87%
Sep 2025 0.8× 10.00%
42 more quarters

Against its own ten years

Low 0.6× High 4.2×
Ten-year median 1.0×
Current reading's percentile 75

P/S ratio against peers

Company P/S ratio
VTRS Viatris Inc. 1.5×
TAK Takeda Pharmaceutical Co. compare 2.1×
ELAN Elanco Animal Health Incorporated compare 2.3×
HLN Haleon PLC Sponsored ADR compare 2.6×
TEVA Teva Pharmaceutical Industries Ltd. compare 2.8×
RDY Dr. Reddy's Laboratories Ltd compare 3.0×
ZTS Zoetis Inc. compare 3.5×
NBIX Neurocrine Biosciences, Inc. compare 4.1×
UTHR United Therapeutics Corporation compare 7.2×
Drug Manufacturers Specialty & Generic industry median 2.1×
Healthcare sector median 3.4×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on VTRS